A Phase 1, Double-Blind, Placebo-Controlled, Randomized, Single and Multiple Ascending Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SIF001 in Healthy Subjects and in a Patient Cohort With Epilepsy
Latest Information Update: 15 Jul 2025
At a glance
- Drugs SIF 001 (Primary)
- Indications Epilepsy
- Focus Adverse reactions
Most Recent Events
- 15 Jul 2025 New trial record